| [1] |
Mete O, Asa SL, Gill AJ, et al. Overview of the 2022 WHO classification of paragangliomas and pheochromocytomas[J]. Endocr Pathol, 2022, 33(1): 90-114.
doi: 10.1007/s12022-022-09704-6
pmid: 35285002
|
| [2] |
Berends AMA, Lenders JWM, Kerstens MN. Update on clinical characteristics in the evaluation of phaeochromocytoma and paraganglioma[J]. Best Pract Res Clin Endocrinol Metab, 2024, 38(6): 101953.
doi: 10.1016/j.beem.2024.101953
|
| [3] |
Ardicli B, User IR, Ciftci AÖ, et al. Approach to pheochromocytoma and paraganglioma in children and adolescents: a retrospective clinical study from a tertiary care center[J]. JJ Pediatr Urol, 2021, 17(3): 400.e1-400.e7.
|
| [4] |
Park H, Kim MS, Lee J, et al. Clinical presentation and treatment outcomes of children and adolescents with pheochromocytoma and paraganglioma in a single center in Korea[J]. Front Endocrinol (Lausanne), 2020, 11: 610746.
doi: 10.3389/fendo.2020.610746
|
| [5] |
Casey RT, Hendriks E, Deal C, et al. International consensus statement on the diagnosis and management of phaeochromocytoma and paraganglioma in children and adolescents[J]. Nat Rev Endocrinol, 2024, 20(12): 729-748.
doi: 10.1038/s41574-024-01024-5
pmid: 39147856
|
| [6] |
Kuo MJM, Nazari MA, Jha A, et al. Pediatric metastatic pheochromocytoma and paraganglioma: clinical presentation and diagnosis, genetics, and therapeutic approaches[J]. Front Endocrinol (Lausanne), 2022, 13: 936178.
doi: 10.3389/fendo.2022.936178
|
| [7] |
Shah MH, Goldner WS, Benson AB, et al. Neuroendocrine and adrenal tumors, version 2.2021, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2021, 19(7): 839-868.
doi: 10.6004/jnccn.2021.0032
|
| [8] |
Peard L, Cost NG, Saltzman AF. Pediatric pheo-chromocytoma: current status of diagnostic imaging and treatment procedures[J]. Curr Opin Urol, 2019, 29(5): 493-499.
doi: 10.1097/MOU.0000000000000650
|
| [9] |
Pamporaki C, Casey RT. Current views on paediatric phaeochromocytoma and paraganglioma with a focus on newest guidelines[J]. Best Pract Res Clin Endocrinol Metab, 2024: 101957.
|
| [10] |
Stachowicz-Stencel T, Pasikowska N, Synakiewicz A. Pheochromocytoma and paraganglioma in children and adolescents[J]. Acta Biochim Pol, 2023, 70(3): 487-493.
doi: 10.18388/abp.2020_6955
pmid: 37717273
|
| [11] |
中华医学会内分泌学分会. 嗜铬细胞瘤和副神经节瘤诊断治疗专家共识(2020版)[J]. 中华内分泌代谢杂志, 2020, 36(9): 737-750.
|
|
Endocrinology CSO. Expert consensus on the diagnosis and treatment of pheochromocytoma and paraganglioma (2020)[J]. Zhonghua Neifenmidaixie Zazhi, 2020, 36(9): 737-750.
|
| [12] |
王伟. 2022儿童和青少年高血压专家共识[J]. 中国合理用药探索, 2022, 19(12): 10-22.
|
|
Wang W. Hypertension in children and adolescents[J]. Zhongguo Heliyongyao Tansuo, 2022, 19(12): 10-22.
|
| [13] |
Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for molecular pathology[J]. Genet Med, 2015, 17(5): 405-424.
doi: 10.1038/gim.2015.30
pmid: 25741868
|
| [14] |
Nazari MA, Jha A, Kuo MJM, et al. Paediatric phaeochromocytoma and paraganglioma: a clinical update[J]. Clin Endocrinol (Oxf), 2024, 101(5): 446-454.
doi: 10.1111/cen.v101.5
|
| [15] |
Choat H, Derrevere K, Knight L, et al. SDHB-associated paraganglioma in a pediatric patient and literature review on hereditary pheochromocytoma-paraganglioma syndromes[J]. Case Rep Endocrinol, 2014, 2014: 502734.
|
| [16] |
Jochmanova I, Abcede AMT, Guerrero RJS, et al. Clinical characteristics and outcomes of SDHB-related pheochromocytoma and paraganglioma in children and adolescents[J]. J Cancer Res Clin Oncol, 2020, 146(4): 1051-1063.
doi: 10.1007/s00432-020-03138-5
pmid: 32062700
|
| [17] |
Virgone C, Andreetta M, Avanzini S, et al. Pheo-chromocytomas and paragangliomas in children: data from the Italian Cooperative Study (TREP)[J]. Pediatr Blood Cancer, 2020, 67(8): e28332.
doi: 10.1002/pbc.v67.8
|
| [18] |
Geroula A, Deutschbein T, Langton K, et al. Pheo-chromocytoma and paraganglioma: clinical feature-based disease probability in relation to catecholamine biochemistry and reason for disease suspicion[J]. Eur J Endocrinol, 2019, 181(4): 409-420.
doi: 10.1530/EJE-19-0159
|
| [19] |
Batsis M, Dagalakis U, Stratakis CA, et al. Attention deficit hyperactivity disorder in pediatric patients with pheochromocytoma and paraganglioma[J]. Horm Metab Res, 2016, 48(8): 509-513.
doi: 10.1055/s-0042-106725
pmid: 27171833
|
| [20] |
Horton C, LaDuca H, Deckman A, et al. Universal germline panel testing for individuals with pheochromocytoma and paraganglioma produces high diagnostic yield[J]. J Clin Endocrinol Metab, 2022, 107(5): e1917-e1923.
|
| [21] |
Seabrook A, Vasudevan A, Neville K, et al. Genotype-phenotype correlations in paediatric and adolescent phaeochromocytoma and paraganglioma: a cross-sectional study[J]. Arch Dis Child, 2024, 109(3): 201-208.
doi: 10.1136/archdischild-2023-325419
pmid: 38071512
|
| [22] |
Wong MY, Andrews KA, Challis BG, et al. Clinical practice guidance: surveillance for phaeochromocytoma and paraganglioma in paediatric succinate dehydrogenase gene mutation carriers[J]. Clin Endocrinol (Oxf), 2019, 90(4): 499-505.
doi: 10.1111/cen.2019.90.issue-4
|
| [23] |
Lenders JWM, Kerstens MN, Amar L, et al. Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension[J]. J Hypertens, 2020, 38(8): 1443-1456.
doi: 10.1097/HJH.0000000000002438
pmid: 32412940
|
| [24] |
Giacché M, Tacchetti MC, Agabiti-Rosei C, et al. Pheochromocytoma-paraganglioma syndrome: a multiform disease with different genotype and phenotype features[J]. Biomedicines, 2024, 12(10):2385.
doi: 10.3390/biomedicines12102385
|
| [25] |
Plouin PF, Amar L, Dekkers OM, et al. European society of endocrinology clinical practice guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma[J]. Eur J Endocrinol, 2016, 174(5): G1-G10.
|
| [26] |
Nölting S, Bechmann N, Taieb D, et al. Personalized management of pheochromocytoma and paraganglioma[J]. Endocr Rev, 2022, 43(2): 199-239.
doi: 10.1210/endrev/bnab019
|
| [27] |
Jha A, Taïeb D, Carrasquillo JA, et al. High-specific-activity--(131)I-MIBG versus (177)Lu-DOTATATE targeted radionuclide therapy for metastatic pheochromocytoma and paraganglioma[J]. Clin Cancer Res, 2021, 27(11): 2989-2995.
doi: 10.1158/1078-0432.CCR-20-3703
|
| [28] |
Carrasquillo JA, Chen CC, Jha A, et al. Systemic radiopharmaceutical therapy of pheochromocytoma and paraganglioma[J]. J Nucl Med, 2021, 62(9): 1192-1199.
doi: 10.2967/jnumed.120.259697
|
| [29] |
Urquhart C, Fleming B, Harper I, et al. The use of temozolomide in paediatric metastatic phaeo-chromocytoma/paraganglioma: a case report and literature review[J]. Front Endocrinol (Lausanne), 2022, 13: 1066208.
doi: 10.3389/fendo.2022.1066208
|
| [30] |
Li M, Prodanov T, Meuter L, et al. Recurrent Disease in Patients With Sporadic Pheochromocytoma and Paraganglioma[J]. J Clin Endocrinol Metab, 2023, 108(2): 397-404.
doi: 10.1210/clinem/dgac563
|